Development of anti-influenza virus drugs I: Improvement of oral absorption and in vivo anti-influenza activity of Stachyflin and its derivatives

Pharmaceutical Research

Volumn 16, Issue 7, 1999, Pages 1041-1046

  Yagi, Shigenori ^a   Ono, Junko ^a   Yoshimoto, Jun ^a   Sugita, Ken Ichi ^a   Hattori, Naohiko ^a   Fujioka, Toshihiro ^a   Fujiwara, Tamio ^a   Sugimoto, Hirohiko ^a   Hirano, Koichiro ^a   Hashimoto, Naofumi ^a  

^a SHIONOGI AND CO LTD   (Japan)

Author keywords

Anti influenza virus drug; Influenza; Oral absorption; PEG; Phosphate ester prodrug

Indexed keywords

2,3,6,6ALPHA,7,8,9,9ALPHA,10,11,12,13 DODECAHYDRO 5,11 HYDROXY 6ALPHA, 7,10,10 TETRAMETHYL 3 OXO 1H BENZO[I]BENZOPYRANO[2,3 E]ISOINDOLE; ANTIVIRUS AGENT; HYDROXYPROPYLMETHYLCELLULOSE; INDOLE DERIVATIVE; MACROGOL 400; MACROGOL 4000; STACHYFLIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; EXPERIMENTAL INFECTION; GASTROINTESTINAL ABSORPTION; IN VIVO STUDY; INFLUENZA; INFLUENZA VIRUS; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ABSORPTION; ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; DOGS; INJECTIONS, INTRAPERITONEAL; INTESTINAL ABSORPTION; INTESTINE, SMALL; MALE; MICE; MICE, INBRED BALB C; MOUTH MUCOSA; ORTHOMYXOVIRIDAE INFECTIONS; PHOSPHORIC ACID ESTERS; POLYETHYLENE GLYCOLS; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; SESQUITERPENES; SOLUBILITY; VEHICLES;

EID: 0032772410     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018983715982     Document Type: Article

References (25)

1. T. Taishi, S. Takechi, and S. Mori. First total synthesis of (±)-Stachyflin. Tetrahedron Lett. 39:4347-4350 (1998).
2. J. Yoshimoto, N. Hattori, M. Kakui, H. Iwasaki, H, Sugimoto, and T. Fujiwara. Identification of a phenotypically irreversible HA conformational change inhibitor. Arch. Virol. (in press).
3. L. H. Pinto, L. J. Holsinger, and R. A. Lamb. Influenza virus M2 protein has ion channel activity. Cell 69:517-528 (1992).
4. C. Schroeder, C.-M Ford, S.-A. Wharton, and A. J. Hay. Functional reconstitution in lipid vesicles of influenza virus M2 protein expressed by baculovirus: Evidence for proton transfer activity, J. Gen. Viol. 75:3477-3484 (1994).
5. R. J. Sugrue and A. J. Hay. Structural characteristics of the M2 protein of influenza A viruses: Evidence that it forms a tetrameric channel. Virology 180:617-624 (1991).
6. A. J. Hay. Potential targets and actions of antiviral agents against influenza viruses. Chem. Scr. 26:77-81 (1986).
7. A. J. Hay. The action of adamantamines against influenza a viruses: inhibition of the M2 ion channel protein. Semin. Virol. 3:21-30 (1992).
8. R. M. Atkinson, C. Bedford, K. J. Child, and E. G. Tomich. Effect of particle size on blood griseofulvin-levels in man. Nature 193:588-589 (1962).
9. K. B. Choudhari and N. M. Sanghavi. Dissolution behavior and characterization of diazepam-pullulan coground mixtures. Int. J. Pharm. 89:207-211 (1993).
10. A. B. Straughn, M. C. Meyer, G. Raghow, and K. Potenberg. Bioavailability of microsize and ultramicrosize griseofulvin products in man. J. Pharmacokinet. Biopharm. 8:347-362 (1980).
11. W. E. Barrett and J. R. Bianche. The bioavailavility of ultramicrosize griseofulvin (GRIS-PEG) tablets in man. Curr. Ther. Res. 18:501-509 (1980).
12. J. H. Fincher. Particle-size of drugs and its relationship to absorption and activity. J. Pharm. Sci. 57:1825-1835 (1968).
13. F. Nimmerfall and J. Rosenthaler. Dependence area under the curve on proquazone particle size and in vitro dissolution rate. J. Pharm. Sci. 69:605-607 (1980).
14. H. E. Paul, K. J. Hayes, M. F. Paul, and A. R. Borgmann. Laboratory studies with nitrofurantoin. J. Pharm. Sci. 56:882-885 (1967).
15. A. S. Ridolfo, L. Thompkins, L. D. Bechtol, and R. H. Carmichael. Benoxaprofen, a new anti-inflammatory agent: particle size effect on dissolution rate and oral absorption in humans. J. Pharm. Sci. 68:850-852 (1979).
16. S-L Lin, J. Menig, and L. Lachman. Interdependence of physiological surfactant and drug particle size on the dissolution behavior of water-insoluble drugs. J. Pharm Sci. 57:2413-2148 (1968).
17. R. L. Oberle and T. L. Moore. Evaluation of nonionic surfactants to improve solubility and oral absorption of CGS-9896. Pharm. Res. 10:Suppl., S222 (1993).
18. A. B. Straughn, M. C. Mayer, G. Raghow, and K. Rotenberg. Bioavailability of microsize and ultramicrosize griseofuluvin products in man. J. Pharmacokin. Biopharm. 8:347-362 (1980).
19. I. Sugimoto, A. Kuchiki, H. Nakagawa, K. Togo, S. Kondo, I. Iwane, and K. Takahashi. Dissolution and absorption of nifedipine from nifedipine-polyvinylpyrrolidone coprecipitate. Drug Der. Ind. Pharm. 6:137-160 (1980).
20. N. Hashimoto, T. Fujioka, K. Hayashi, K. Odaguchi, T. Toyoda, M. Nakayama, and K. Hirano. Renin inhibitor: Relationship between molecular structure and oral absorption. Pharm. Res. 11:1443-1447 (1994).
21. S. A. Varia and V. J. Stella. Phenytoin prodrugs V: In vivo evaluation of some water-soluble phenytoin prodrugs in dogs. J. Pharm. Sci. 73:1080-1087 (1984).
22. S. A. Varia and V. J. Stella. Phenytoin prodrugs VI: In vivo evaluation of a phosphate ester prodrug of phenytoin after parenteral administration to rats. J. Pharm. Sci. 73:1087-1090 (1984).
23. D. Fleisher, K. C. Johnson, B. H. Stewart, and G. L. Amidon. Oral absorption of 21-corticosteroid esters: A function of aqueous stability and intestinal enzyme activity and distribution. J. Pharm. Sci. 75:934-939 (1986).
24. C. Sessa, M. Zucchetti, T. Cerny, O. Pagani, F. Cavalli, M. De Jong, D. Gentili, C. McDaniel, C. Prins, L. Schacter, B. Winograd, and M. D'Incalci. Phase I clinical and pharmacokinetic study of oral etoposide phosphate. J. Clin. Oncol. 13:200-209 (1995).
25. N. Muranushi, T. Yoshikawa, M. Nishiuchi, T. Oguma, K. Hirano, and H. Yamada. Characteristics of the intestinal absorption of 7432-S, a new orally active cephalosporin. 18th Symposium on Drug Metabolism and Action. Abstr. 55-58 (1986).